U.S. Markets close in 2 hrs 44 mins

Synlogic, Inc. (SYBX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.3000-0.0700 (-2.95%)
As of 01:13PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.3700
Bid2.2900 x 900
Ask2.3000 x 800
Day's Range2.2900 - 2.4300
52 Week Range2.0700 - 5.1100
Avg. Volume507,519
Market Cap120.447M
Beta (5Y Monthly)1.75
PE Ratio (TTM)N/A
EPS (TTM)-1.5480
Earnings DateNov 03, 2021 - Nov 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.33
  • TipRanks

    These 2 Penny Stocks Are Set for Massive Gains, Says Oppenheimer

    What kind of stocks stir up controversy like no other? Penny stocks. These tickers trading for less than $5 per share have earned a reputation as some of the most divisive names on Wall Street, with these plays either met with open arms or given the cold shoulder. It’s understandable why some investors are wary. Those opposed are quick to point out that there could be a very real reason these stocks are changing hands for pocket change, with the low share prices often masking obstacles like weak

  • PR Newswire

    Synlogic Presents Data Demonstrating Reductions in Plasma Phenylalanine Levels in Patients with Phenylketonuria Treated with SYNB1618

    Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage company bringing the transformative potential of synthetic biology to medicine, today announced presentation of interim data from the company's Phase 2 SynPheny-1 clinical trial showing that treatment with the investigational Synthetic BioticTM medicine SYNB1618 resulted in significant reductions in plasma phenylalanine (Phe) levels in patients with phenylketonuria (PKU). Results were presented today by Dr. Jerry Vockley, MD, PhD in a late-breaking

  • Zacks

    AbbVie's (ABBV) Skyrizi Gets Nod for Psoriatic Arthritis in EU

    AbbVie (ABBV) secures approval in the EU for Skyrizi to treat adult patients with active psoriatic arthritis.